G1 Therapeutics Inc. (GTHX)
G1 Therapeutics Statistics
Share Statistics
G1 Therapeutics has 52.76M shares outstanding. The number of shares has increased by 0.91% in one year.
| Shares Outstanding | 52.76M |
| Shares Change (YoY) | 0.91% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 38.21% |
| Shares Floating | 39.15M |
| Failed to Deliver (FTD) Shares | 98.07K |
| FTD / Avg. Volume | 4.4% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -3.29 and the forward PE ratio is null. G1 Therapeutics's PEG ratio is 0.05.
| PE Ratio | -3.29 |
| Forward PE | n/a |
| PS Ratio | 1.91 |
| Forward PS | null |
| PB Ratio | 4.46 |
| P/FCF Ratio | -4.12 |
| PEG Ratio | 0.05 |
Enterprise Valuation
G1 Therapeutics has an Enterprise Value (EV) of 182.68M.
| EV / Sales | 2.21 |
| EV / EBITDA | -4.68 |
| EV / EBIT | -4.77 |
| EV / FCF | -4.77 |
Financial Position
The company has a current ratio of 3.87, with a Debt / Equity ratio of 1.46.
| Current Ratio | 3.87 |
| Quick Ratio | 3.45 |
| Debt / Equity | 1.46 |
| Debt / EBITDA | -1.47 |
| Debt / FCF | -1.49 |
| Interest Coverage | -3.94 |
Financial Efficiency
Return on Equity is -135.55% and Return on Invested Capital is -48.62%.
| Return on Equity | -135.55% |
| Return on Assets | -39.47% |
| Return on Invested Capital | -48.62% |
| Revenue Per Employee | $825.11K |
| Profits Per Employee | $-479.67K |
| Employee Count | 100 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 0.58 |
Taxes
| Income Tax | 3.12M |
| Effective Tax Rate | -6.95% |
Stock Price Statistics
The stock price has increased by 74.63% in the last 52 weeks. The beta is 1.68, so G1 Therapeutics's price volatility has been higher than the market average.
| Beta | 1.68 |
| 52-Week Price Change | 74.63% |
| 50-Day Moving Average | 5.75 |
| 200-Day Moving Average | 4.06 |
| Relative Strength Index (RSI) | 84.39 |
| Average Volume (20 Days) | 2.23M |
Income Statement
In the last 12 months, G1 Therapeutics had revenue of 82.51M and earned -47.97M in profits. Earnings per share was -0.93.
| Revenue | 82.51M |
| Gross Profit | 75.32M |
| Operating Income | -39.53M |
| Net Income | -47.97M |
| EBITDA | -39.01M |
| EBIT | -34.81M |
| Earnings Per Share (EPS) | -0.93 |
Balance Sheet
The company has 32.28M in cash and 57.17M in debt, giving a net cash position of -24.89M.
| Cash & Cash Equivalents | 32.28M |
| Total Debt | 57.17M |
| Net Cash | -24.89M |
| Retained Earnings | -779.99M |
| Total Assets | 98.69M |
| Working Capital | 55.42M |
Cash Flow
In the last 12 months, operating cash flow was -38.34M and capital expenditures 0, giving a free cash flow of -38.34M.
| Operating Cash Flow | -38.34M |
| Capital Expenditures | 0 |
| Free Cash Flow | -38.34M |
| FCF Per Share | -0.74 |
Margins
Gross margin is 91.28%, with operating and profit margins of -47.91% and -58.13%.
| Gross Margin | 91.28% |
| Operating Margin | -47.91% |
| Pretax Margin | -54.36% |
| Profit Margin | -58.13% |
| EBITDA Margin | -47.28% |
| EBIT Margin | -47.91% |
| FCF Margin | -46.46% |
Dividends & Yields
GTHX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -30.4% |
| FCF Yield | -24.3% |
Analyst Forecast
The average price target for GTHX is $3, which is -58.1% lower than the current price. The consensus rating is "Hold".
| Price Target | $3 |
| Price Target Difference | -58.1% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -8.17 |
| Piotroski F-Score | 2 |